Modality
mAb
MOA
BCL-2i
Target
CD38
Pathway
RAS/MAPK
Prostate CaNASH
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Feb 2031
Phase 2Current
NCT07099057
1,843 pts·Prostate Ca
2023-12→2031-02·Recruiting
NCT03090851
2,253 pts·Prostate Ca
2021-10→2026-10·Terminated
4,096 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-247mo awayPh2 Data· Prostate Ca
2031-02-234.9y awayPh2 Data· Prostate Ca
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2026-10-24 · 7mo away
Prostate Ca
Ph2 Data
2031-02-23 · 4.9y away
Prostate Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07099057 | Phase 2 | Prostate Ca | Recruiting | 1843 | EDSS |
| NCT03090851 | Phase 2 | Prostate Ca | Terminated | 2253 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Tezecilimab | Takeda | NDA/BLA | Tau |